Biotech Showcase™ 2017: BioInvent discusses recent Pfizer immunotherapy alliance

January 26, 2017
Three years after setting out to turn BioInvent around, company president and CEO Michael Oredsson tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, how the company is developing its immunotherapy offering. With tumor-associated myeloid cells, BioInvent secured a deal with Pfizer at the end of 2016, while it intends to go it alone with its regulatory T cell approach.
Previous Video
BIO-Europe Spring® 2017 Offers Partnering Opportunities for Biotech, Pharma and Finance
BIO-Europe Spring® 2017 Offers Partnering Opportunities for Biotech, Pharma and Finance

BIO-Europe Spring | March 20–22, 2017, in Barcelona, Spain | Access a world of opportunities through life s...

Next Video
Biotech Showcase™ 2017: Market-ready Advicenne seeks partners and EUR 40 million VC funds
Biotech Showcase™ 2017: Market-ready Advicenne seeks partners and EUR 40 million VC funds

With a focus on pediatric neurology and nephrology, Dr. Luc-André Granier, founder, CEO and medical directo...